Health Care/Hospital
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (...
2023-09-28 20:00
2221
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the treatm...
2023-09-28 20:00
1398
Health In Tech Partners With Tall Tree Administrators to Extend Health Insurance Options for Small Businesses
The Collaboration Provides Self-Funded Clients Access to Tailored Health Plans and Ancillary Products STUART, Fla., Sept. 28, 2023 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is excited to ann...
2023-09-28 20:00
1319
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
2023-09-28 18:09
1527
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azaciti...
2023-09-28 10:07
1656
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and muci...
2023-09-28 09:46
1998
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
2023-09-27 22:03
1671
Emotional Link LLC CEO Naoto Sato Interviews Associate Professor Mai Uchida, Harvard Medical School, on "How to deal with Blowing up on SNS"
TOKYO, Sept. 27, 2023 /PRNewswire/ -- Emotional Link LLC
2023-09-27 22:00
2406
OBiO has launched its state-of-the-art GMP production facility Intelli-M to expedite innovative and advanced therapies to patients who are in need.
SHANGHAI, Sept. 27, 2023 /PRNewswire/ -- In Shanghai, China, on August, OBiO Technology, a prominent leader in the Cell and Gene Therapy (CGT) field and a Contract Development and Manufacturing Organization, proudly unveiled the official launch of its state-of-the-art GMP production facility, chr...
2023-09-27 21:00
1589
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical's targeted protein degradation (TPD) pipeline SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focuse...
2023-09-27 08:30
1495
ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation
SAN DIEGO and SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation,...
2023-09-27 00:00
1766
China Jo-Jo Drugstores Announces $2.59 Million Registered Direct Offering
HANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2023-09-26 21:00
3323
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update
Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report resu...
2023-09-26 20:51
1514
WuXi Vaccines Launches Its First Vaccines CDMO Site in China
SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou,China. The opening will add drug substanc...
2023-09-26 15:41
1484
Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch
* Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the produc...
2023-09-25 20:15
1485
Zhongchao Inc. Introduces PRO-Based Disease Management Model for Lung Cancer Patients
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the introduction of its Patient-Reported Outcome (PRO) -based sy...
2023-09-25 20:00
1407
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-09-25 19:00
1502
Xtep Unveils Milestone Brand Strategy Upgrade to Offer World-Class Running Shoes and Gears
Xtep's international roadmap sprints for win-win success with global partners BEIJING, Sept. 25, 2023 /PRNewswire/ -- Xtep International Holdings Limited ("Xtep"), a leading professional sportswear company, has launched its milestone brand strategy upgrade of "World-class Running Shoes of China X...
2023-09-25 18:48
2141
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment
----- YL201 Phase I/II Investigators Meeting was successfully held in Guangzhou, China GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ -- On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered inGuangzhou to participate in the YL201 P...
2023-09-23 18:29
2593
Concord Medical Reports Financial Results for the First Half of 2023
BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extens...
2023-09-23 05:00
5639
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
